Background. Patients with systemic lupus erythematosus (SLE) experience photosensitivity, with exposure to ultraviolet light B (UVB) driving lupus flares and triggering symptoms like joint pain, fatigue, and cutaneous lesions. Although the mechanism(s) linking UVB exposure to systemic effects are unclear, type I interferons (IFNs) are known to play a role. Our previous work has shown that TRIM21, an autoantigen in SLE, functions as a negative regulator on the pathways driving IFN expression. Here we explore how TRIM21 functions to regulate both local and systemic inflammation following UVB exposure and that altered expression may drive cutaneous inflammation and photosensitivity in SLE. Methods. WT (C57BL/6) and Trim21-/- mice were irradiated with UVB (100mJ/cm2) on shaved dorsal region of the mice on consecutive days for 1 and 3 weeks, and UVB induced local cutaneous manifestations and systemic inflammation in blood, spleen and kidney were examined by messenger RNA expression of inflammatory and type I IFN response genes, histology, and flow cytometry. To determine the molecular targets of TRIM21 downstream of UVB, mechanistic studies were performed in bone marrow-derived macrophages (BMDMs) and mouse skin fibroblasts (MDF) from WT and Trim21-/- mice, and TRIM21-/- THP-1 cells. Results. Infiltration of inflammatory cells and induction of type I IFN developed in UVB-exposed areas in both sets of mice. Most notably after UVB exposure, we observed splenomegaly and enhanced expression of IFN-stimulated genes (ISG) in the blood and spleen of Trim21-/- mice. Subsequent analysis showed higher expression of Siglec1, an IFN-inducible protein, on Ly6Chi inflammatory monocytes in the spleen and blood cells of UVB-exposed Trim21-/- mice, indicating a systemic IFN response. Inflammatory chemokines CXCL10 and CXCL12, both important in UVB-induced skin inflammation, were also detected at significantly higher levels in serum of Trim21-/- mice after UVB exposure. In addition, Trim21-/- mice exposed to UVB also demonstrated enhanced total IgG levels in serum accompanied by increased skin deposition of IgG. Altogether, loss of Trim21 in mice results in enhanced systemic IFN-driven responses and mimics increased systemic disease in SLE patients following UVB exposure. TRIM21 acts to restrain RNA/DNA sensing and IFN responses, and enhanced basal and UVB- and cGAMP-dependent Ifnb1 expression was observed in Trim21-/- BMDMs and MDFs. In cells obtained from Trim21/Sting1 double knockout mice, cGAMP and cytoplasmic dsDNA induced Ifnb1 expression was reduced, indicating that TRIM21 regulates Ifnb1 expression through the adaptor protein STING. As TRIM21 is an E3 ligase and known to regulate protein stability, we assessed protein levels of cGAS, DDX41 and STING itself. Mechanistically, we found both degradation of DDX41 and STING levels were affected in stimulated Trim21-/- BMDMs. Taken together, our results indicate that TRIM21 protects against IFN induction at local and systemic levels due to a failure to restrict STING signaling. Understanding the role of TRIM21 in preventing systemic disease will have important understandings of its role in driving increased disease activity and flare in SLE.